What is microdosing of GLP-1 medications? A plain guide to the lower-dose approach

.webp)

You've probably heard of GLP-1 receptor agonists, medications such as semaglutide and tirzepatide, which have become widely used for weight management. Less familiar is the idea that the standard, maximum dose isn't the only way they're used. That's the concept behind microdosing GLP-1 medications.
This is an educational overview of what microdosing means and how it differs from standard dosing. It isn't medical advice or a promise of a specific result.
In this context, microdosing refers to using lower-than-standard doses of semaglutide or tirzepatide under clinician guidance. It's not the same as microdosing in other contexts (such as psychedelics), and it isn't about sub-therapeutic amounts. The idea is to work with a lower dose and adjust based on how a person responds, rather than automatically titrating to the maximum.
Standard GLP-1 protocols generally aim to reach a target maximum dose over a set titration schedule. A microdosing approach instead emphasizes finding a lower effective dose and adjusting it based on the individual's response and tolerance, under a provider's supervision. Whether a lower dose is appropriate, and what it should be, is a clinical decision, not a fixed rule.
GLP-1 medications are prescription medications with real considerations, including contraindications and possible side effects. A microdosing approach is still medical treatment that requires clinical oversight. At Luvo, semaglutide and tirzepatide are offered as compounded medications through a clinician-guided program; compounded medications are not FDA-approved, and a licensed provider reviews your health history before prescribing.
Whether a microdosing approach fits depends on your health, your history, and a provider's assessment. Explore Luvo's Microdosing Program to learn more and speak with a licensed provider.